ClinicalTrials.gg
RecruitingNCT05388643Updated Apr 6, 2026

Early Detection of Gestational Diabetes Mellitus in Pregnancy

An interventional study of Enhanced First Trimester GDM Screening and Routine Gestational Diabetes Screening in Gestational Diabetes Mellitus in Pregnancy and Pregnancy, High Risk, sponsored by University of Massachusetts, Worcester. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by University of Massachusetts, Worcester · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 251 studies in Diabetes, Gestational with a site in United States — 52 open to participants now, 65 under way, 2 of them phase 3. Diabetes, Gestational · United States.

Planned enrollment
97th of 194
80 · median 80
Started
2025
with 24 others
No phase
154 of 251
31 open now
Primary completion
2026-12
later than 27 of 64 live
Registered
176th of 251
by date

Among the 251 studies in Diabetes, Gestational with a site in United States, this one is the 97th largest by planned enrollment of the 194 interventional ones that give a count, is one of 25 that started in 2025, is one of 154 with no phase, reaches primary completion later than 27 of the 64 other live ones, and was the 176th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

52 of the 251 studies in Diabetes, Gestational with a site in United States are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Diabetes, Gestational with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to develop an implementation protocol and test the feasibility and acceptability of a first trimester screening protocol for the early detection of gestational diabetes mellitus (GDM).

Read the detailed description

Gestational diabetes mellitus (GDM) is an important contributor to both maternal and neonatal morbidity and mortality in pregnancy. GDM has lifelong complications including an increased risk of developing type 2 diabetes mellitus and cardiovascular disease for women, and their offspring are at higher risk of being obese and also having diabetes in childhood and adolescence. Approximately 1 in 8 pregnancies is impacted by gestational diabetes mellitus worldwide. First trimester GDM screening is varied due to conflicting national guidelines, and the best strategy is unknown. The goal of the proposed research is to develop an implementation protocol and test the feasibility and acceptability of a first trimester screening protocol for the early detection of GDM. The investigators will utilize a pilot randomized controlled trial to recruit 80 high-risk pregnant women in the first trimester, of whom half will receive protocolized early GDM screening with serum biomarkers before 12 weeks and the remaining half will receive the current standard of care with screening between 24 and 28 weeks of gestation with possible early screening based on provider discretion.

03

Conditions studied

  • Gestational Diabetes Mellitus in Pregnancy
  • Pregnancy, High Risk

Browse trials for

Keywords

  • Pregnancy
  • Gestational Diabetes
  • Screening
  • Maternal Outcomes
  • Neonatal Outcomes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1) age greater than or equal to 18 years old,
  • 2) singleton gestation less than or equal to 12 weeks at initial obstetric visit,
  • 3) receiving prenatal care at UMMHC and plans to deliver at UMMHC,
  • 4) able and willing to provide ,
  • 5) English or Spanish speaking, and
  • 6) are at high risk for developing GDM by ACOG clinical risk factor guidelines.

Exclusion criteria

Exclusion Criteria:

  • 1) known diagnosis of pre-existing pregestational diabetes,
  • 2) plan to receive prenatal care or deliver outside of UMMHC,
  • 3) inability to complete oral glucose tolerance test (e.g. gastric bypass surgery history, gastric dumping syndrome history, vomiting of oral glucose tolerance test), or
  • 4) systemic use.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Enhanced First Trimester GDM Screening

    Women who are randomly assigned to this condition will be required to have early glucose screening with a prediction model composed of additional clinical risk factors and serum biomarkers (triglycerides, PAPP-A, and lipocalin-2) with their initial prenatal laboratory assessment.

    Diagnostic Test: Enhanced First Trimester GDM Screening

  • Active comparator
    Standard of Care GDM Screening

    Women who will be randomized to the comparison condition of usual standard of care will undergo routine standard of care. The standard of care will consist of routine screening for diabetes in pregnancy between 24 to 28 weeks of gestation via the two-step screening method with possible early screening with either plasma fasting glucose, oral glucose tolerance test, or hemoglobin A1c at the providers discretion to represent true clinical practice.

    Diagnostic Test: Routine Gestational Diabetes Screening

Interventions

  • Diagnostic testEnhanced First Trimester GDM Screening

    Women who are randomly assigned to this condition will be required to have early glucose screening with a prediction model composed of additional clinical risk factors and serum biomarkers (triglycerides, PAPP-A, and lipocalin-2) with their initial prenatal laboratory assessment.

  • Diagnostic testRoutine Gestational Diabetes Screening

    Women who will be randomized to the comparison condition of usual standard of care will undergo routine standard of care. The standard of care will consist of routine screening for diabetes in pregnancy between 24 to 28 weeks of gestation via the two-step screening method with possible early screening with either plasma fasting glucose, oral glucose tolerance test, or hemoglobin A1c at the providers discretion to represent true clinical practice.

    Also known as: Third Trimester Screening

06

What researchers measure

Primary outcomes

  1. Gestational Diabetes Mellitus

    Confirmed diagnosis of GDM based on 3 hour 100 gram glucose tolerance test

    Time frame: In pregnancy (24-28 weeks gestation)

Secondary outcomes

  1. Mode of Delivery

    Mode of delivery (Vaginal versus Cesarean delivery)

    Time frame: At Birth

  2. Neonatal Birthweight

    Neonatal Birthweight

    Time frame: At Birth

  3. Number of Participants with Shoulder Dystocia

    Number of Participants with Shoulder Dystocia

    Time frame: At Birth

  4. Number of participants with brachial plexus injury

    Number of participants with brachial plexus injury

    Time frame: At Birth

  5. APGAR Score

    APGAR Score (range 0 to 10, with 10 being the best)

    Time frame: At Birth

  6. Neonatal Intensive Care Unit Admission

    Admission to Level 2 or greater neonatal ICU and length of stay

    Time frame: At delivery and within first 2 days of life

  7. Gestational Age at Delivery

    Gestational Age at Delivery

    Time frame: At Birth

  8. Patient Satisfaction with Diabetes Screening Method

    This will be assessed by the Patient Satisfaction Survey questionnaire, which is scored out of 30, with 30 being the highest score)

    Time frame: Postpartum day 1 after birth

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Sweeting AN, Wong J, Appelblom H, Ross GP, Kouru H, Williams PF, Sairanen M, Hyett JA. A Novel Early Pregnancy Risk Prediction Model for Gestational Diabetes Mellitus. Fetal Diagn Ther. 2019;45(2):76-84. doi: 10.1159/000486853. Epub 2018 Jun 13. PubMed 29898442 ↗
  • Nanda S, Savvidou M, Syngelaki A, Akolekar R, Nicolaides KH. Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenat Diagn. 2011 Feb;31(2):135-41. doi: 10.1002/pd.2636. Epub 2010 Dec 28. PubMed 21268030 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 17 months is below that.

Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2022
First posted
May 24, 2022
StartActual
Jul 1, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05388643
Responsible party
Gianna Wilkie (Principal Investigator, University of Massachusetts, Worcester) — Principal investigator
First posted
May 24, 2022
Start date
Jul 1, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Apr 6, 2026

Study contacts

Gianna L Wilkie, MD
Contact
Gianna.Wilkie@umassmemorial.org
77743642523
Gianna Wilkie, MD
principal investigator · University of Massachusetts, Worcester

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion